Trial reportBJU international2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Trial report in BJU international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00090545 (A Phase II Study of BAY 43-9006), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2014Pooled it
- Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Journal of human hypertension · 2013Pooled it
- Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).Cancer research and treatment · 2018Trial
- Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).Investigational new drugs · 2016Trial
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.BJU international · 2013Trial
- A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.Prostate cancer and prostatic diseases · 2012Trial
- An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer.British journal of cancer · 2024Article
- Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Review
- Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells.EXCLI journal · 2021Article
- Angiogenesis Inhibition in Prostate Cancer: An Update.Cancers · 2020Review
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.Prostate cancer and prostatic diseases · 2019Observational
- Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Frontiers in oncology · 2018Review
- Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.Oncotarget · 2017Article
- Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Targeted oncology · 2016Review
- Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition.Translational andrology and urology · 2016Article
- Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Clinical pharmacokinetics · 2016Review
- Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.Journal of translational medicine · 2015Article
- Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.Journal of bone oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer. Secondary endpoints included pharmacokinetics, toxicity analysis and overall survival. PATIENTS AND
methodsThe study was an open-label, phase II, two-stage design, focusing on the results from the second stage, as criteria for progression were modified after completing the first stage. Sorafenib was given at a dose of 400 mg orally twice daily in 28-day cycles. Clinical and laboratory assessments were done every 4 weeks, and radiographic scans were obtained every 8 weeks.
resultsTwenty-four patients were accrued in the second stage; the median (range) age was 66 (49-85) years, the on-study prostate-specific antigen level was 68.45 (5.8-995) ng/mL, the Gleason score 8 (6-9) and Eastern Cooperative Oncology Group status 1 (in 17 patients). Of the 24 patients, 21 had previous chemotherapy with docetaxel. All patients had bony metastases, either alone (in 11) or with soft-tissue disease (in 13). One patient had a partial response; 10 patients had stable disease (median duration 18 weeks, range 15-48). At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months. For the whole trial of 46 patients the median survival was 18.3 months. Most frequent toxicities included hand-foot skin reaction (grade 2 in nine patients, grade 3 in three), rash, abnormalities in liver function tests, and fatigue.
conclusionsSorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.